*For each participant and variable of interest (e.g., percentage of vaginal acts where study gel was used in the last 7 days prior to the follow-up visit), we first calculated the participant's mean v
*All participants had been reported AFB+ by the field laboratory on ≥2 pre-enrolment sputum specimens. †The usual reason for vitD or vitD placebo to be withheld/deferred was hypercalcaemia.
*One enrolled participant was later found to not meet eligibility criteria and was subsequently discontinued from product use, one enrolled participant was erroneously thought to not meet eligibility
